Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neuroscience Bulletin
Published in: Neuroscience Bulletin 3/2024

Open Access 28-08-2023 | Neuropathic Pain | Original Article

Cytochrome P450 26A1 Contributes to the Maintenance of Neuropathic Pain

Authors: De-Li Cao, Ling-Jie Ma, Bao-Chun Jiang, Qiang Gu, Yong-Jing Gao

Published in: Neuroscience Bulletin | Issue 3/2024

Login to get access

Abstract

The cytochrome P450 proteins (CYP450s) have been implicated in catalyzing numerous important biological reactions and contribute to a variety of diseases. CYP26A1, a member of the CYP450 family, carries out the oxidative metabolism of retinoic acid (RA), the active metabolite of vitamin A. Here we report that CYP26A1 was dramatically upregulated in the spinal cord after spinal nerve ligation (SNL). CYP26A1 was mainly expressed in spinal neurons and astrocytes. HPLC analysis displayed that the content of all-trans-RA (at-RA), the substrate of CYP26A1, was reduced in the spinal cord on day 7 after SNL. Inhibition of CYP26A1 by siRNA or inhibition of CYP26A1-mediated at-RA catabolism by talarozole relieved the SNL-induced mechanical allodynia during the maintenance phase of neuropathic pain. Talarozole also reduced SNL-induced glial activation and proinflammatory cytokine production but increased anti-inflammatory cytokine (IL-10) production. The RA receptors RARα, RXRβ, and RXRγ were expressed in spinal neurons and glial cells. The promoter of Il-10 has several binding sites for RA receptors, and at-RA directly increased Il-10 mRNA expression in vitro. Finally, intrathecal IL-10 attenuated SNL-induced neuropathic pain and reduced the activation of astrocytes and microglia. Collectively, the inhibition of CYP26A1-mediated at-RA catabolism alleviates SNL-induced neuropathic pain by promoting the expression of IL-10 and suppressing glial activation. CYP26A1 may be a potential therapeutic target for the treatment of neuropathic pain.
Literature
1.
Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6: 1–42.PubMed
2.
Guengerich FP. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 1997, 106: 161–182.PubMed
3.
Nebert DW, Gonzalez FJ. P450 genes: Structure, evolution, and regulation. Annu Rev Biochem 1987, 56: 945–993.PubMed
4.
5.
Rasheed MSU, Mishra AK, Singh MP. Cytochrome P450 2D6 and parkinson’s disease: Polymorphism, metabolic role, risk and protection. Neurochem Res 2017, 42: 3353–3361.
6.
Song BJ, Abdelmegeed MA, Cho YE, Akbar M, Rhim JS, Song MK, et al. Contributing roles of CYP2E1 and other cytochrome P450 isoforms in alcohol-related tissue injury and carcinogenesis. Adv Exp Med Biol 2019, 1164: 73–87.PubMed
7.
Gilroy DW, Edin ML, De Maeyer RP, Bystrom J, Newson J, Lih FB, et al. CYP450-derived oxylipins mediate inflammatory resolution. Proc Natl Acad Sci U S A 2016, 113: E3240–E3249.PubMedPubMedCentral
8.
Lutz JD, Dixit V, Yeung CK, Dickmann LJ, Zelter A, Thatcher JE, et al. Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase. Biochem Pharmacol 2009, 77: 258–268.PubMed
9.
Ross AC, Zolfaghari R. Cytochrome P450s in the regulation of cellular retinoic acid metabolism. Annu Rev Nutr 2011, 31: 65–87.PubMedPubMedCentral
10.
11.
12.
Maden M. Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci 2007, 8: 755–765.PubMed
13.
Gudas LJ. Emerging roles for retinoids in regeneration and differentiation in normal and disease states. Biochim Biophys Acta 2012, 1821: 213–221.PubMed
14.
Abu-Abed S, Dollé P, Metzger D, Beckett B, Chambon P, Petkovich M. The retinoic acid-metabolizing enzyme, CYP26A1, is essential for normal hindbrain patterning, vertebral identity, and development of posterior structures. Genes Dev 2001, 15: 226–240.PubMedPubMedCentral
15.
Bowles J, Knight D, Smith C, Wilhelm D, Richman J, Mamiya S, et al. Retinoid signaling determines germ cell fate in mice. Science 2006, 312: 596–600.ADSPubMed
16.
Koubova J, Menke DB, Zhou Q, Capel B, Griswold MD, Page DC. Retinoic acid regulates sex-specific timing of meiotic initiation in mice. Proc Natl Acad Sci U S A 2006, 103: 2474–2479.ADSPubMedPubMedCentral
17.
Sakai Y, Meno C, Fujii H, Nishino J, Shiratori H, Saijoh Y, et al. The retinoic acid-inactivating enzyme CYP26 is essential for establishing an uneven distribution of retinoic acid along the anterio-posterior axis within the mouse embryo. Genes Dev 2001, 15: 213–225.PubMedPubMedCentral
18.
Ricard MJ, Gudas LJ. Cytochrome p450 cyp26a1 alters spinal motor neuron subtype identity in differentiating embryonic stem cells. J Biol Chem 2013, 288: 28801–28813.PubMedPubMedCentral
19.
Larsen R, Proue A, Scott EP, Christiansen M, Nakagawa Y. The thalamus regulates retinoic acid signaling and development of parvalbumin interneurons in postnatal mouse prefrontal cortex. eNeuro 2019, 6: ENEURO.0018-ENEURO.0019.2019.PubMed
20.
Wang Y, Zolfaghari R, Ross AC. Cloning of rat cytochrome P450RAI (CYP26) cDNA and regulation of its gene expression by all-trans-retinoic acid in vivo. Arch Biochem Biophys 2002, 401: 235–243.PubMed
21.
Xi J, Yang Z. Expression of RALDHs (ALDH1As) and CYP26s in human tissues and during the neural differentiation of P19 embryonal carcinoma stem cell. Gene Expr Patterns 2008, 8: 438–442.PubMed
22.
White JA, Ramshaw H, Taimi M, Stangle W, Zhang A, Everingham S, et al. Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism. Proc Natl Acad Sci U S A 2000, 97: 6403–6408.ADSPubMedPubMedCentral
23.
Reijntjes S, Gale E, Maden M. Generating gradients of retinoic acid in the chick embryo: Cyp26C1 expression and a comparative analysis of the Cyp26 enzymes. Dev Dyn 2004, 230: 509–517.PubMed
24.
Tahayato A, Dolle P, Petkovich M. Cyp26C1 encodes a novel retinoic acid-metabolizing enzyme expressed in the hindbrain, inner ear, first branchial arch and tooth buds during murine development. Gene Expr Patterns 2003, 3: 449–454.PubMed
25.
Zhang Y, Crofton EJ, Smith TES, Koshy S, Li D, Green TA. Manipulation of retinoic acid signaling in the nucleus accumbens shell alters rat emotional behavior. Behav Brain Res 2019, 376: 112177.PubMedPubMedCentral
26.
Donnelly CR, Andriessen AS, Chen G, Wang K, Jiang C, Maixner W, et al. Central nervous system targets: Glial cell mechanisms in chronic pain. Neurotherapeutics 2020, 17: 846–860.PubMedPubMedCentral
27.
Lu HJ, Gao YJ. Astrocytes in chronic pain: Cellular and molecular mechanisms. Neurosci Bull 2023, 39: 425–439.PubMed
28.
Jiang BC, Liu T, Gao YJ. Chemokines in chronic pain: Cellular and molecular mechanisms and therapeutic potential. Pharmacol Ther 2020, 212: 107581.PubMed
29.
van Neerven S, Nemes A, Imholz P, Regen T, Denecke B, Johann S, et al. Inflammatory cytokine release of astrocytes in vitro is reduced by all-trans retinoic acid. J Neuroimmunol 2010, 229: 169–179.PubMed
30.
van Neerven S, Regen T, Wolf D, Nemes A, Johann S, Beyer C, et al. Inflammatory chemokine release of astrocytes in vitro is reduced by all-trans retinoic acid. J Neurochem 2010, 114: 1511–1526.PubMed
31.
Kampmann E, Johann S, van Neerven S, Beyer C, Mey J. Anti-inflammatory effect of retinoic acid on prostaglandin synthesis in cultured cortical astrocytes. J Neurochem 2008, 106: 320–332.PubMed
32.
Wang X, Allen C, Ballow M. Retinoic acid enhances the production of IL-10 while reducing the synthesis of IL-12 and TNF-α from LPS-stimulated monocytes/macrophages. J Clin Immunol 2007, 27: 193–200.PubMed
33.
Dheen ST, Jun Y, Yan Z, Tay SS, Ling EA. Retinoic acid inhibits expression of TNF-alpha and iNOS in activated rat microglia. Glia 2005, 50: 21–31.PubMed
34.
Zhang ZJ, Cao DL, Zhang X, Ji RR, Gao YJ. Chemokine contribution to neuropathic pain: Respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons. Pain 2013, 154: 2185–2197.PubMedPubMedCentral
35.
Hylden JL, Wilcox GL. Intrathecal morphine in mice: A new technique. Eur J Pharmacol 1980, 67: 313–316.PubMed
36.
Jiang BC, Zhang WW, Yang T, Guo CY, Cao DL, Zhang ZJ, et al. Demethylation of G-protein-coupled receptor 151 promoter facilitates the binding of Krüppel-like factor 5 and enhances neuropathic pain after nerve injury in mice. J Neurosci 2018, 38: 10535–10551.PubMedPubMedCentral
37.
Sakhi AK, Gundersen TE, Ulven SM, Blomhoff R, Lundanes E. Quantitative determination of endogenous retinoids in mouse embryos by high-performance liquid chromatography with on-line solid-phase extraction, column switching and electrochemical detection. J Chromatogr A 1998, 828: 451–460.PubMed
38.
Jiang BC, Cao DL, Zhang X, Zhang ZJ, He LN, Li CH, et al. CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. J Clin Invest 2016, 126: 745–761.PubMedPubMedCentral
39.
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53: 55–63.PubMed
40.
Thatcher JE, Zelter A, Isoherranen N. The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid. Biochem Pharmacol 2010, 80: 903–912.PubMedPubMedCentral
41.
42.
Zhuang ZY, Gerner P, Woolf CJ, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005, 114: 149–159.PubMed
43.
Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 2003, 23: 4017–4022.PubMedPubMedCentral
44.
Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996, 10: 940–954.PubMed
45.
Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004, 328: 1–16.PubMed
46.
Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol 2006, 66: 606–630.PubMed
47.
Sisignano M, Angioni C, Park CK, Meyer Dos Santos S, Jordan H, Kuzikov M, et al. Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. Proc Natl Acad Sci U S A 2016, 113: 12544.ADSPubMedPubMedCentral
48.
Li F, Zhu W, Gonzalez FJ. Potential role of CYP1B1 in the development and treatment of metabolic diseases. Pharmacol Ther 2017, 178: 18–30.PubMedPubMedCentral
49.
Lim S, Alshagga M, Ong CE, Chieng JY, Pan Y. Cytochrome P450 4B1 (CYP4B1) as a target in cancer treatment. Hum Exp Toxicol 2020, 39: 785–796.PubMed
50.
Priyanka SH, Thushara AJ, Rauf AA, Indira M. All trans retinoic acid attenuates markers of neuroinflammation in rat brain by modulation of SIRT1 and NFκB. Neurochem Res 2018, 43: 1791–1801.PubMed
51.
Behairi N, Belkhelfa M, Rafa H, Labsi M, Deghbar N, Bouzid N, et al. All-trans retinoic acid (ATRA) prevents lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment in aged rats. J Neuroimmunol 2016, 300: 21–29.PubMed
52.
Romero-Sandoval EA, Alique M, Moreno-Manzano V, Molina C, Lucio FJ, Herrero JF. The oral administration of retinoic acid enhances nociceptive withdrawal reflexes in rats with soft-tissue inflammation. Inflamm res 2004, 53: 297–303.PubMed
53.
Hamed EA, Mohamed Farghaly HS, Abdel Mola AF, Fahmi MK, Makhlouf MM, Balfas MA. Role of monocyte chemoattractant protein-1, stromal derived factor-1 and retinoic acid in pathophysiology of neuropathic pain in rats. J Basic Clin Physiol Pharmacol 2016, 27: 411–424.PubMed
54.
Stoppie P, Borgers M, Borghgraef P, Dillen L, Goossens J, Sanz G, et al. R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents. J Pharmacol Exp Ther 2000, 293: 304–312.PubMed
55.
Verfaille CJ, Coel M, Boersma IH, Mertens J, Borgers M, Roseeuw D. Oral R115866 in the treatment of moderate to severe facial acne vulgaris: An exploratory study. Br J Dermatol 2007, 157: 122–126.PubMed
56.
Verfaille CJ, Thissen CA, Bovenschen HJ, Mertens J, Steijlen PM, van de Kerkhof PC. Oral R115866 in the treatment of moderate to severe plaque-type psoriasis. J Eur Acad Dermatol Venereol 2007, 21: 1038–1046.PubMed
57.
Schrage K, Koopmans G, Joosten EA, Mey J. Macrophages and neurons are targets of retinoic acid signaling after spinal cord contusion injury. Eur J Neurosci 2006, 23: 285–295.PubMed
58.
Aoto J, Nam CI, Poon MM, Ting P, Chen L. Synaptic signaling by all-trans retinoic acid in homeostatic synaptic plasticity. Neuron 2008, 60: 308–320.PubMedPubMedCentral
59.
Chen N, Napoli JL. All-trans-retinoic acid stimulates translation and induces spine formation in hippocampal neurons through a membrane-associated RARalpha. FASEB J 2008, 22: 236–245.PubMed
60.
Stoney PN, Fragoso YD, Saeed RB, Ashton A, Goodman T, Simons C, et al. Expression of the retinoic acid catabolic enzyme CYP26B1 in the human brain to maintain signaling homeostasis. Brain Struct Funct 2016, 221: 3315–3326.PubMed
61.
Zhang ZJ, Jiang BC, Gao YJ. Chemokines in neuron-glial cell interaction and pathogenesis of neuropathic pain. Cell Mol Life Sci 2017, 74: 3275–3291.PubMed
62.
Tsuda M, Inoue K. Neuron-microglia interaction by purinergic signaling in neuropathic pain following neurodegeneration. Neuropharmacology 2016, 104: 76–81.PubMed
63.
Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR. Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav Immun 2007, 21: 642–651.PubMed
64.
Milligan ED, Zapata V, Chacur M, Schoeniger D, Biedenkapp J, O’Connor KA, et al. Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci 2004, 20: 2294–2302.PubMed
65.
Nam Y, Kim JH, Kim JH, Jha MK, Jung JY, Lee MG, et al. Reversible induction of pain hypersensitivity following optogenetic stimulation of spinal astrocytes. Cell Rep 2016, 17: 3049–3061.PubMed
66.
Milligan ED, Sloane EM, Langer SJ, Hughes TS, Jekich BM, Frank MG, et al. Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain 2006, 126: 294–308.PubMed
67.
Ledeboer A, Jekich BM, Sloane EM, Mahoney JH, Langer SJ, Milligan ED, et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root Ganglia in rats. Brain Behav Immun 2007, 21: 686–698.PubMed
68.
Kim WM, Jeong CW, Lee SH, Kim YO, Cui JH, Yoon MH. The intrathecally administered kappa-2 opioid agonist GR89696 and interleukin-10 attenuate bone cancer-induced pain through synergistic interaction. Anesth Analg 2011, 113: 934–940.PubMed
69.
Zhou Z, Peng X, Hao S, Fink DJ, Mata M. HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia. Gene Ther 2008, 15: 183–190.PubMed
70.
Ma L, Peng S, Wei J, Zhao M, Ahmad KA, Chen J, et al. Spinal microglial β-endorphin signaling mediates IL-10 and exenatide-induced inhibition of synaptic plasticity in neuropathic pain. CNS Neurosci Ther 2021, 27: 1157–1172.PubMedPubMedCentral
71.
Milligan ED, Penzkover KR, Soderquist RG, Mahoney MJ. Spinal interleukin-10 therapy to treat peripheral neuropathic pain. Neuromodulation 2012, 15: 520–526;discussion526.
72.
Lu Y, Jiang BC, Cao DL, Zhang ZJ, Zhang X, Ji RR, et al. TRAF6 upregulation in spinal astrocytes maintains neuropathic pain by integrating TNF-α and IL-1β signaling. Pain 2014, 155: 2618–2629.PubMedPubMedCentral
73.
Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: Distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci 2008, 28: 5189–5194.PubMedPubMedCentral
Metadata
Title
Cytochrome P450 26A1 Contributes to the Maintenance of Neuropathic Pain
Authors
De-Li Cao
Ling-Jie Ma
Bao-Chun Jiang
Qiang Gu
Yong-Jing Gao
Publication date
28-08-2023
Publisher
Springer Nature Singapore
Published in
Neuroscience Bulletin / Issue 3/2024
Print ISSN: 1673-7067
Electronic ISSN: 1995-8218
DOI
https://doi.org/10.1007/s12264-023-01101-1

Other articles of this Issue 3/2024

Neuroscience Bulletin 3/2024 Go to the issue

Review

A Comprehensive Overview of the Neural Mechanisms of Light Therapy

Review

The Multiple Roles of Autophagy in Neural Function and Diseases

Research Highlight

Prefrontocortical Astrocytes Regulate Dominance Hierarchy in Male Mice

Research Highlight

Nociceptors and Macrophages in Bacterial Meningitis: Partners in Crime?

Original Article

A Non-canonical Excitatory PV RGC–PV SC Visual Pathway for Mediating the Looming-evoked Innate Defensive Response

Review

Ion Channel Dysregulation Following Intracerebral Hemorrhage